1,271 results on '"Neuvonen, Pertti"'
Search Results
2. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions
3. Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment.
4. Voriconazole greatly increases the exposure to oral buprenorphine
5. Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition
6. Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects
7. Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study
8. Increased incidence of Merkel cell carcinoma among younger statin users
9. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol
10. In vitro and in vivo entrapment of bupivacaine by lipid dispersions
11. Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults
12. Drug-Related Inadvertent Deaths in a University Hospital – A Declining Trend
13. Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril
14. High performance liquid chromatography–tandem mass spectrometry for the determination of bile acid concentrations in human plasma
15. St John’s wort greatly reduces the concentrations of oral oxycodone
16. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine
17. Effect of grapefruit juice on the bioactivation of prasugrel
18. The role of concentration−effect relationships in the QTc interval prolongation: case sotalol
19. Effect of voriconazole on the pharmacokinetics of oral buprenorphine: O1–01
20. A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole
21. Rifampicin markedly decreases the exposure to oral and intravenous tramadol
22. Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction
23. S-ketamine concentrations are greatly increased by grapefruit juice
24. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid
25. Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone: A Randomized, Three-Phase, Crossover, Placebo-Controlled Study
26. Pharmacokinetics of Intravenous Paracetamol in Elderly Patients
27. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast
28. Elimination of Intravenous Oxycodone in the Elderly: A Pharmacokinetic Study in Postoperative Orthopaedic Patients of Different Age Groups
29. Long-term persistence with statin therapy: A nationwide register study in Finland
30. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
31. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren
32. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
33. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
34. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial
35. Voriconazole drastically increases exposure to oral oxycodone
36. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib
37. Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin
38. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo
39. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine
40. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
41. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide
42. Voriconazole and fluconazole increase the exposure to oral diazepam
43. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation
44. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen
45. Additional file 1 of Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition
46. Additional file 2 of Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition
47. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone
48. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone
49. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
50. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.